Abstract: A therapeutic lens for the treatment of an epithelial defect comprises a layer of therapeutic material disposed over the stroma and/or Bowman's membrane to inhibit water flow from the tear liquid to the stroma and/or Bowman's membrane, such that corneal deturgescence can be restored to decrease corneal swelling and light scattering. The layer may cover and protect nerve fibers to decrease pain. The layer may comprise an index of refraction to inhibit light scatter from an anterior surface of the stroma and/or Bowman's membrane. The lens may comprise a curved anterior surface that provides functional vision for the patient when the epithelium regenerates. The layer of therapeutic material can be positioned on the eye in many ways, for example with a spray that is cured to adhere the layer to the exposed surface of the stroma and/or Bowman's membrane.

Abstract: An apparatus and method for reducing intraocular pressure in a patient's eye is provided. A deformable intraocular member having a relaxed state with a relaxed profile having a first width, a first energized state with a first profile having a second width, and a second energized state with a second profile having a third width is provided. The deformable intraocular member relaxed state width is greater than the width of a lens capsule which surrounds a lens of the patient's eye prior to cataract surgery. The second energized state width is greater than the patient's lens capsule width after cataract surgery and smaller than the width in the relaxed state. The deformable intraocular member in the second energized state is configured to urge deformation of the lens capsule to thereby promote opening of a trabecular meshwork and canal of Schlemm of the patient's eye to promote drainage of aqueous humor from an anterior chamber and reduce intraocular pressure in the patient's eye.

Abstract: An intracorneal lens that is inserted between stromal layer of a cornea of an eye, and provides two distinct regions of focality. The lens includes a central region with a thinner wall and a surrounding region with a thicker wall.

Abstract: Hydrogel coated multifocal intraocular implantable lens having an anti-glare edge surrounded by a hydrogel ring having nutrient passage capabilities.

Abstract: Targeted eye drop dispenser having concentric target rings of highly colored material aligned over and about the dispensing orifice. Highly visible material target rings aid in alignment of the dispensing orifice over the center of the human eye for self-dispensing of eye drops by the user of the targeted eye drop dispenser. An alternative embodiment includes a lighted target area.

Abstract: A defined serumfree medical solution for applications in Ophthalmology, that contains one or more cell nutrient supplements which maintains and enhances the preservation of eye tissues, including human corneal tissues at low temperatures (2.degree. C. to 15.degree. C.). This solution is composed of a defined aqueous nutrient and electrolyte solution, supplemented with a glycosaminoglycan(s), a deturgescent agent(s), an energy source(s), a buffer system(s), an antioxidant(s), membrane stabilizing components, antibiotic(s), ATP precursors and nutrient cell supplements.

Abstract: This is a non-primate vitreal replacement process that quantitates the inflammatory response to viscoelastic agents or solutions. More specifically, the rabbit vitreal replacement process consists of the surgical replacement of a small volume of the central gel vitreous of the rabbit with a viscoelastic agent or solution, and measuring the invasion of white blood cells in the vitreous and anterior chamber at 48 hours post injection. Additional parameters measured are anterior chamber flare, haze and flare in the vitreal chamber, ocular fundus clarity, presence of iris congestion, lens involvement, corneal clarity, conjunctival congestion and conjunctival swelling. In this process, the rabbit is evaluated prior to injection of the viscoelastic agent or solution and 48 hours post injection. Each parameter is evaluated on a scale of 0 to 5. A non-inflammatory sample consists of a mean total score of equal to or less than one or a vitreal cell count less than 50 cells/mm.sup.3.

Abstract: A viscoelastic solution including a buffered solution, 0.01-10% chondroitin sulfate, 0.01-10% hydroxypropyl methylcellulose, and 0.01-10% sodium hyaluronate, pH adjusted to 6.0-8.0 at a osmolarity between 200-400 mOsmol/L. The buffered solution can be HEPES buffered minimal essential medium (MEM), phosphate buffered saline (PBS), or buffered balanced salt solution. A cell growth factor or cell growth supplement can also be included in the solution.

Abstract: Viscoelastic solution including a buffered solution, 0.01-8% chondroitin sulfate, 0.1-8% hydroxypropyl methylcellulose, pH adjusted to 6.0-8.0 at a osmolality between 200-400 mOsmol/L. The buffered solution can be HEPES buffered minimum essential media (MEM), phosphate buffer saline (PBS), buffered balanced salt solution, or TC199. A cell growth factor or cell growth supplement is included in the solution.

Abstract: A defined serumfree medical solution for applications in Ophthalmology, that contains one or more cell nutrient supplements which maintains and enhances the preservation of eye tissues, including human corneal tissues at low temperatures (2.degree. C. to 15.degree. C.). This solution is composed of a defined aqueous nutrient and electrolyte solution, supplemented with a glycosaminoglycan(s), a deturgescent agent(s), an energy source(s), a buffer system(s), an antioxidant(s), membrane stabilizing components, antibiotic(s), ATP precursors and nutrient cell supplements.

Abstract: This is a non-primate vitreal replacement process that quantitates the inflammatory response to viscoelastic agents or solutions. More specifically, the rabbit vitreal replacement process consists of the surgical replacement of a small volume of the central gel vitreous of the rabbit with a viscoelastic agent or solution, and measuring the invasion of white blood cells in the vitreous and anterior chamber at 48 hours post injection. Additional parameters measured are anterior chamber flare, haze and flare in the vitreal chamber, ocular fundus clarity, presence of iris congestion, lens involvement, corneal clarity, conjunctival congestion and conjunctival swelling. In this process, the rabbit is evaluated prior to injection of the viscoelastic agent or solution and 48 hours post injection. Each parameter is evaluated on a scale of 0 to 5. A non-inflammatory sample consists of a mean total score of equal to or less than one or a vitreal cell count less than 50 cells/mm.sup.3.

Abstract: A corneal holder, amenable for use in both a corneal storage system and a corneal cutting system with minimal physical manipulation of the corneal tissue itself. The holder provides a passageway through the apertures of both a base member and a cap member that is configured to allow a cutting device to be passed into cutting contact with a predetermined portion of the corneal tissue. The holder allows radial orientation of the predetermined portion in order to limit astigmatism; as well as constriction of the periphery of the corneal tissue during storage in order to alleviate swelling of the tissue due to fluid absorption.

Abstract: Viscoelastic solution including a buffered solution, 0.01-8% chondroitin sulfate, 0.1-8% hydroxypropyl methylcellulose, pH adjusted to 6.0-8.0 at a osmolality between 200-400 mOsmol/L. The buffered solution can be HEPES buffered minimum essential media (MEM), phosphate buffer saline (PBS), buffered balanced salt solution, or TC199. A cell growth factor or cell growth supplement is included in the solution.

Abstract: An intraocular lens denoted as a YAG dimpled lens or dimpled YAG lens, which includes a barrier rim and a YAG spacer area in a posterior surface of the lens. The barrier rim is 2-4 mm in longitudinal length and the YAG spacer is 3-4 mm in longitudinal length across the surface diameter of an optic of the intraocular lens. The lens optic can be either plano-convex or bi-convex. A cutout for the dimpled YAG spacer is provided which is either a convave or a substantially rectangular geometrical configuration in the posterior surface of the lens. The YAG spacer can also include a trough or a groove geometrical configuration, such as in the configurations of a Maltese cross, a circular trough or groove, or a circular trough or groove with a Maltese cross therein. The barrier rim is 33% to 80% of the total surface are of the posterior surface of the lens.

Abstract: A process for establishing functional human corneal tissue consisting of an enhanced contact-inhibited endothelial monolayer derived from isolated human corneal endothelial cells with other integral corneal layers remaining intact. The process is divided into four integral parts.1. Isolation of human corneal endothelial cells from donor corneas.2. Establishment of a human corneal endothelial cell line which involves the establishment of primary cell cultures, proliferation, and continued maintenance and subculturing of these cells in vitro.3. The utilization of long term storage of isolated human corneal endothelial cells at -80.degree. C.4. Utilizing these isolated corneal endothelial cells from the above processes to enhance the corneal endothelial monolayer of human donor corneas to be used for penetrating keratoplasty.Two distinct methods of corneal endothelial enhancement may be utilized.

Abstract: An additive for intraocular irrigation solution or surgical solution which provides the anterior chamber and posterior chamber of the eye with protection during surgical procedures that require irrigation. The additive for the solutions is composed of a balanced salt solution containing dextrose supplemented with chondroitin sulfate. Other chemical compositions can supplement the additive.

Abstract: Intracorneal or epicorneal lens with a plurality of fixation holes spaced about the outer circumference of the lens. The lens can be of a soft material, such as hydrogel, a high refractive index material such as polysulfone, polycarbonate, or polyethylene, or any other material. The lens can also be coated with any suitable material, such as hydrogel or glycosaminoglycan.

Abstract: An intracorneal lens with at least one hole such as central pinhole, or a, plurality of pinholes or the like; and, a material filling the holes or a material filling the pinholes, and coating the lens. The intracorneal lens can be of any high index of refraction material. The material filling the holes as well as coating the lens can be a gas permeable polymer or metabolite permeable material, a biocompatible polymer or biocompatible material, or a neutral or negatively charged material.

Abstract: Intraocular lens including loop haptic members each affixed at more than one point to a soft skirt of an optic or to a soft optic for torsional rigidity of the loop haptic member and for preventing loop rotation or pull out in an optic. The loop haptic members each include a main loop haptic member, and two branch members proceeding from the main loop haptic member to affix in securement holes in the edge or surface of an optic. The loops' securement end points include conically shaped end like members which engage within the soft portion of the IOL.

Abstract: A surgical or irrigation solution which provides the anterior and posterior chamber of the eye with protection during surgical procedures that require irrigation. This irrigation solution is composed of a HEPES buffered Eagle's Minimum Essential Media (MEM) with Earle's Salts, without phenol red, supplemented with mixed isomers of 99% pure, chondroitin sulfate, MEM non-essential amino acids, 2-mercaptoethanol, and sodium pyruvate. Other solutions include a balanced salt solution, chondroitin sulfate, buffers and 2-mercaptoethanol. The solution can also be used in other surgical or medical applications.